Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK, Amira Team Up In $425 Million Asthma Collaboration

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal gives GSK rights to Amira’s FLAP inhibitors for the treatment of respiratory and cardiovascular disease.

You may also be interested in...



BMS Bets On Amira's IPF Drug In $325M Acquisition

The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.

BMS Bets On Amira's IPF Drug In $325M Acquisition

The deal expands BMS's inflammatory disease holdings while bringing double-digit returns to the six-year-old startup's earliest investors.

Regulus Is On The Launch “Platform” With $20M Series A Financing

Alnylam, Isis keep ownership of joint venture for now, but status change could bring more investors aboard by 2011.

Related Content

Topics

UsernamePublicRestriction

Register

PS067341

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel